1-4 of 4
Victoria Falco
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 2 Study of Minimal Residual Disease (MRD)-Adapted Front Line Venetoclax and Obinutuzumab in Fit Patients with Chronic Lymphocytic Leukemia (CLL): Effect of Obinutuzumab on Tumor Lysis Syndrome (TLS) Risk and Safety of Outpatient Venetoclax Dose Escalation

Lindsey E. Roeker, Andrew D. Zelenetz, Jae H. Park, Andriy Derkach, Mark Blaine Geyer, Prioty Islam, Lorenzo Falchi, Maria Lia Palomba, Anita Kumar, Gilles Salles, Jennifer Kimberly Lue, Aaron D. Goldberg, Bita Fakhri, Catherine C. Coombs, Victoria Falco, Gail Panton, Dianna Tyznar, Dhara Soni, Lauren Nogan, Sonia Lebowitz, Katherine Blesie, Monica Shah, Sarah Court, Christopher E. Jensen, Anthony R. Mato, Meghan C. Thompson
Journal: Blood
Blood (2023) 142 (Supplement 1): 4657.
https://doi.org/10.1182/blood-2023-181661
Published: 2023
Journal Articles

A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach

Lindsey E. Roeker, Lori A. Leslie, Jake D. Soumerai, Victoria Falco, Gail Panton, Andrew D. Zelenetz, Lorenzo Falchi, Jae H Park, Camila Pena-Velasquez, Sonia Lebowitz, Kristen Battiato, Carissa Laudati, Meghan C. Thompson, David J. Straus, Yehudit Fox, Elizabeth McCarthy, Sabrina Kdiry, Rosalba Martignetti, Hari P. Miskin, Peter Sportelli, Anthony R. Mato
Journal: Blood
Blood (2021) 138 (Supplement 1): 395.
https://doi.org/10.1182/blood-2021-146999
Published: 2021
Journal Articles

First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl

Jae H Park, Eric S. Winer, Scott F. Huntington, Gottfried von Keudell, Shreya Vemuri, Madhulika Shukla, Julie C Kinoshita, Victoria Falco, Steven D. Gore, Richard M. Stone, Omar Abdel-Wahab, Martin S. Tallman
Journal: Blood
Blood (2021) 138 (Supplement 1): 43.
https://doi.org/10.1182/blood-2021-151074
Published: 2021
Journal Articles

A Once Daily, Oral, Triple Combination of BTK Inhibitor, mTOR Inhibitor and IMiD for Treatment of Relapsed/Refractory Richter's Transformation and De Novo Diffuse Large B-Cell Lymphoma

Anthony R. Mato, MD, Stephen J. Schuster, MD, Francine M. Foss, MD, Iris Isufi, MD, Shalin K. Kothari, MD, Wei Ding, MD PhD, Danielle M. Brander, MD, Andrea Sitlinger, MD, Allison C. Rosenthal, D.O., Jose F. Leis, MD PhD, Han W. Tun, MD, Kaitlin Kennard, RN, BSN, Allison R. Nelson, RN, Victoria Falco, BSN, Celina J. Komari, BS, Amber B. Koehler, PA-C, MS, Rachel Stowe, RN, Wei He, PhD, Albert Kearney, PhD, Min Gui, PhD, Tim McKinlay, Lindsey E Roeker, MD, Meghan C. Thompson, MD, Scott F. Huntington, MD MPH
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–22.
https://doi.org/10.1182/blood-2020-138896
Published: 2020